Avelumab: Additional Phase Ib data

Data from a cohort of 145 patients with previously untreated NSCLC in the open-label, dose-escalation, international Phase Ib JAVELIN Solid Tumor trial showed

Read the full 237 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE